05-361 | Anti-NFκB p52 Antibody

200 µg  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited AvailabilityLimited Availability
In Stock 
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

      Special Offers


      Contact Customer Service

      Click To Print This Page


      Replacement Information

      Key Spec Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      HEMSA, IP, WBMPurifiedMonoclonal Antibody
      Catalogue Number05-361
      Brand Family Upstate
      Trade Name
      • Upstate
      DescriptionAnti-NFκB p52 Antibody
      Alternate Names
      • DNA-binding factor KBF2
      • Lymphocyte translocation chromosome 10
      • Oncogene Lyt-10
      • nuclear factor of kappa light chain gene enhancer in B-cells 2
      • nuclear factor of kappa light polypeptide gene enhancer in B-cells 2
      • nuclear factor of kappa light polypeptide gene enhancer in B-cells 2
      Background InformationThe NFκB transcription factor was originally identified as a protein complex consisting of a DNA binding subunit and an associated protein. The DNA binding subunit is functionally related to c-Rel p75 and Rel B p68. The p50 subunit was initially believed to be a functionally unique protein derived from the amino terminus of a precursor designated p105. A cDNA has been isolated that encodes an alternative DNA binding subunit of NFκB. It is synthesized as a protein that is expressed in a variety of cell types and, like p105, undergoes cleavage to generate its NFκB subunit, in this case a protein designated p52 (previously referred to as p49). In contrast to p50 derived from p105, p52 acts in synergy with p65 to stimulate the HIV enhancer in transiently transfected Jurkat cells.
      Product Information
      • Jurkat whole cell lysate, HeLa nuclear extract.

        Included Positive Antigen Control:
        Catalog # 12-309, HeLa nuclear extract. Add an equal volume of Laemmli reducing sample buffer to 5-10 µL of extract and boil for 5 minutes to reduce the preparation. Load 20 µg of reduced lysate per lane for minigels.
      PresentationPurified mouse monoclonal IgG2a in buffer containing 0.1 M Tris-glycine, pH 7.4, 0.15 M NaCl, 0.05% sodium azide.
      ApplicationAnti-NFκB p52 Antibody is a Mouse Monoclonal Antibody for detection of NFκB p52 also known as DNA-binding factor KBF2, Lymphocyte translocation chromosome 10, Oncogene Lyt-10 & has been validated in EMSA, IP & WB.
      Key Applications
      • Electrophoretic Mobility Shift Assay
      • Immunoprecipitation
      • Western Blotting
      Application NotesImmunoprecipitation:
      4 µg of a previous lot immunoprecipitated NFκB p52 and its p100 precursor from 500 µg of HeLa nuclear extract cell lysate.

      Gel Shift Assay:
      A previous lot of this antibody used 2 µg per gel shift assay (Bours, V., 1993).
      Biological Information
      ImmunogenGST-fusion protein corresponding to amino acids 1-444 of human NFκB p52 subunit (Schmidt, R., 1991;Bours, V., 1992).
      ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
      SpecificityThis antibody recognizes the p52 subunit of NFκB and its p100 precursor.
      Species Reactivity
      • Human
      Species Reactivity NoteHuman. Does not cross-react with mouse or rat; other species cross-reactivity is unknown.
      Antibody TypeMonoclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryNFKB has been detected in numerous cell types that express cytokines, chemokines, growth factors, cell adhesion molecules, and some acute phase proteins in health and in various disease states. NFKB is activated by a wide variety of stimuli such as cytokines, oxidant-free radicals, inhaled particles, ultraviolet irradiation, and bacterial or viral products. Inappropriate activation of NF-kappa-B has been linked to inflammatory events associated with autoimmune arthritis, asthma, septic shock, lung fibrosis, glomerulonephritis, atherosclerosis, and AIDS. In contrast, complete and persistent inhibition of NF-kappa-B has been linked directly to apoptosis, inappropriate immune cell development, and delayed cell growth. For reviews, see Chen et al. (1999) [PubMed 9895331] and Baldwin (1996) [PubMed 8717528].[supplied by OMIM] .
      Gene Symbol
      • NFKB2
      • LYT10
      • H2TF1
      • LYT-10
      • Lyt10
      Purification MethodProtein G Chromatography
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: Q00653 # Appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65.
      SIZE: 900 amino acids; 96749 Da
      SUBUNIT: Active NF-kappa-B is a heterodimer of an about 52 kDa DNA-binding subunit and the weak DNA-binding subunit p65. Two heterodimers might form a labile tetramer.
      SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).
      DOMAIN: SwissProt: Q00653 The C-terminus of p100 might be involved in cytoplasmic retention, inhibition of DNA-binding by p52 homodimers, and/or transcription activation (By similarity). & The glycine-rich region (GRR) appears to be a critical element in the generation of p52.
      PTM: While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p52 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing. & Subsequent to MAP3K14-dependent serine phosphorylation, p100 polyubiquitination occurs then triggering its proteasome-dependent processing. & Constitutive processing is tightly suppressed by its C- terminal processing inhibitory domain, named PID, which contains the death domain.
      DISEASE: SwissProt: Q00653 # A chromosomal aberration involving NFKB2 is found in a case of B-cell non Hodgkin lymphoma (B-NHL). Translocation t(10;14)(q24;q32) with IGHA1. The resulting oncogene is also called Lyt-10C alpha variant. & A chromosomal aberration involving NFKB2 is found in a cutaneous T-cell leukemia (C-TCL) cell line. This rearrangement produces the p80HT gene which encodes for a truncated 80 kDa protein (p80HT). & In B-cell leukemia (B-CLL) cell line, LB40 and EB308, can be found after heterogeneous chromosomal aberrations, such as internal deletions.
      SIMILARITY: Contains 7 ANK repeats. & Contains 1 death domain. & Contains 1 RHD (Rel-like) domain.
      Molecular Weight52 kDa; precursor at 100 kDa
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality AssuranceRoutinely evaluated by immunoblotting in HeLa nuclear extract or in human Raji cell, but not in mouse 3T3/A31 cell and rat PC 12 cell lysates

      Western Blot Analysis:
      0.5-2 µg/mL of this lot detected NFκB p52 and its p100 precursor in HeLa nuclear extract. A previous lot detected NFκB p52 and its p100 precursor in human Raji cell, but not in mouse 3T3/A31 cell and rat PC 12 cell lysates. Highly recommended for western blotting.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsStable for 1 year at -20°C from date of receipt.

      Handling Recommendations:
      Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
      Packaging Information
      Material Size200 µg
      Transport Information
      Supplemental Information




      Safety Data Sheet (SDS) 

      Certificates of Analysis

      TitleLot Number
      Anti-NF#954;B p52 - 2127184 2127184
      Anti-NF#954;B p52 - 2138399 2138399
      Anti-NF#954;B p52 - JBC1864715 JBC1864715
      Anti-NFB p52 - 2032277 2032277
      Anti-NFB p52 - 2052861 2052861
      Anti-NFB p52 - 2073103 2073103
      Anti-NFB p52 - 2194156 2194156
      Anti-NFB p52 - 2325109 2325109
      Anti-NFB p52 - DAM1462560 DAM1462560
      Anti-NFB p52 - DAM1623212 DAM1623212


      Reference overviewApplicationPub Med ID
      TRAF1 Coordinates Polyubiquitin Signaling to Enhance Epstein-Barr Virus LMP1-Mediated Growth and Survival Pathway Activation.
      Greenfeld, H; Takasaki, K; Walsh, MJ; Ersing, I; Bernhardt, K; Ma, Y; Fu, B; Ashbaugh, CW; Cabo, J; Mollo, SB; Zhou, H; Li, S; Gewurz, BE
      PLoS pathogens  11  e1004890  2015

      Show Abstract
      Western Blotting25996949 25996949
      Cezanne regulates E2F1-dependent HIF2α expression.
      Moniz, S; Bandarra, D; Biddlestone, J; Campbell, KJ; Komander, D; Bremm, A; Rocha, S
      Journal of cell science  128  3082-93  2015

      Show Abstract
      26148512 26148512
      Inducible nitric oxide synthase mediates DNA double strand breaks in Human T-Cell Leukemia Virus Type 1-induced leukemia/lymphoma.
      Baydoun, HH; Cherian, MA; Green, P; Ratner, L
      Retrovirology  12  71  2015

      Show Abstract
      26265053 26265053
      TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK.
      Carmona Arana, JA; Seher, A; Neumann, M; Lang, I; Siegmund, D; Wajant, H
      Frontiers in immunology  5  63  2014

      Show Abstract
      Western Blotting24600451 24600451
      The RelB alternative NF-kappaB subunit promotes autophagy in 22Rv1 prostate cancer cells in vitro and affects mouse xenograft tumor growth in vivo.
      Labouba, I; Poisson, A; Lafontaine, J; Delvoye, N; Gannon, PO; Le Page, C; Saad, F; Mes-Masson, AM
      Cancer cell international  14  67  2014

      Show Abstract
      25788857 25788857
      Regulation of p53 and Rb links the alternative NF-κB pathway to EZH2 expression and cell senescence.
      Iannetti, A; Ledoux, AC; Tudhope, SJ; Sellier, H; Zhao, B; Mowla, S; Moore, A; Hummerich, H; Gewurz, BE; Cockell, SJ; Jat, PS; Willmore, E; Perkins, ND
      PLoS genetics  10  e1004642  2014

      Show Abstract
      25255445 25255445
      Targeting IκB proteins for HIV latency activation: the role of individual IκB and NF-κB proteins.
      Fernandez, G; Zaikos, TD; Khan, SZ; Jacobi, AM; Behlke, MA; Zeichner, SL
      Journal of virology  87  3966-78  2013

      Show Abstract
      23365428 23365428
      The IKK inhibitor Bay 11-7082 induces cell death independent from inhibition of activation of NFκB transcription factors.
      Rauert-Wunderlich, H; Siegmund, D; Maier, E; Giner, T; Bargou, RC; Wajant, H; Stühmer, T
      PloS one  8  e59292  2013

      Show Abstract
      23527154 23527154
      NFκB regulates expression of Polo-like kinase 4.
      Ledoux, AC; Sellier, H; Gillies, K; Iannetti, A; James, J; Perkins, ND
      Cell cycle (Georgetown, Tex.)  12  3052-62  2013

      Show Abstract
      23974100 23974100
      TfR1 interacts with the IKK complex and is involved in IKK-NF-κB signalling.
      Kenneth, NS; Mudie, S; Naron, S; Rocha, S
      The Biochemical journal  449  275-84  2013

      Show Abstract
      23016877 23016877

      Related Products & Applications

      Related Products

      Catalogue Number Description  
      06-413 Anti-NFκB p52 Antibody Show Pricing & Availability
      07-1829 Anti-phospho-NF-kB (p100) (Ser707) Antibody Show Pricing & Availability
      ABS1515 Anti-phospho NFkB p52, (Ser222) Antibody Show Pricing & Availability

      Included Positive Control

      Catalogue Number Description  
      12-309 HeLa Nuclear Extract Show Pricing & Availability


      Life Science Research > Antibodies and Assays > Primary Antibodies